Endometriosis tests advance abroad while U.S. lags for 1 in 10 women

For biopharma and diagnostics developers, endometriosis represents one of the largest unaddressed patient populations in women's health — roughly 1 in 10 women worldwide — yet the standard path to answers still runs through years of symptom management and, often, invasive surgery. New non-invasive tests now used in other countries signal a shifting clinical paradigm, but experts caution they are a 'useful tool but not a complete solution,' underscoring the sensitivity and validation work still ahead. The race is now on for a test that can clear U.S. regulatory hurdles and win over clinicians who have long relied on surgical confirmation.

The case of Zoë Armstrong — a 31-year-old who wept with relief when an ultrasound finally showed signs of endometriosis after roughly two decades of unexplained symptoms — puts a human face on one of women's health's most persistent diagnostic failures. The American College of Obstetricians & Gynecologists reports that patients can wait a decade or more after symptom onset before receiving an endometriosis diagnosis, and the condition affects an estimated 1 in 10 women worldwide. Armstrong's first symptoms were stabbing pains on her left side that repeatedly sent her to the school nurse at age 11; as an adult she endured severe pain, nausea, heavy periods, acne, and rupturing ovarian cysts. After marrying, she described pain like having a tiny fencer inside her. An ultrasound report finally gave her an answer: 'To see it on paper, I was like, I'm not crazy.'

“

The American College of Obstetricians & Gynecologists reports that patients can wait a decade or more after symptom onset before receiving an endometriosis diagnosis, and the condition affects an estimated 1 in 10 women worldwide.

Clinically, endometriosis is best understood as a chronic inflammatory disease in which tissue similar to the uterine lining grows elsewhere in the body — most commonly the bladder, bowel, or ovaries, and in rare cases outside the pelvis. Its exact cause remains unknown, though genetics is thought to play a part. Symptoms vary with the extent and location of lesions and typically include pain during periods, intercourse, and bowel movements, along with bloating, fatigue, and infertility. Dr. Drorit Or of Mount Sinai West in New York describes the toll in plain terms: 'It can be debilitating pain that makes you not be able to go to school or work or be in bed for days at a time.'

The diagnostic bottleneck sits at the center of the problem. Because symptoms overlap with other conditions and definitive diagnosis has historically depended on invasive surgical visualization, patients often cycle through providers for years before answers emerge. For patients, the result is a diagnostic odyssey measured not in weeks but in decades — less a clinical workflow than a failure of early triage and symptom recognition. The reporting notes that new tests used in other countries are raising hopes among both doctors and patients — but they are not currently available in the United States, and some experts expect them to be a useful tool rather than a complete solution. That caveat is telling: it implies non-invasive imaging or biomarker approaches may accelerate triage while still missing the superficial or atypical disease that a surgeon's eye would catch, keeping laparoscopy relevant for now.